Amarin to Present at Cantor Global Healthcare Conference
September 20 2017 - 04:30PM
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, announced today that John F. Thero,
Amarin's president and chief executive officer, is scheduled to
present a general company update at the Cantor Global Healthcare
Conference in New York City on Tuesday, September 26, 2017, at
11:30 a.m. EST.
A live audio webcast of the presentation will be available at:
http://www.amarincorp.com, and will be accessible at the same link
for 30 days.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health. Amarin's product development program
leverages its extensive experience in lipid science and the
potential therapeutic benefits of polyunsaturated fatty acids.
Amarin's clinical program includes a commitment to an ongoing
outcomes study. Vascepa® (icosapent ethyl), Amarin's first
FDA approved product, is a highly-pure, omega-3 fatty acid product
available by prescription. For more information about Vascepa
visit www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.
Availability of other Information about
Amarin
Investors and others should note that we communicate with our
investors and the public using our company website
(www.amarincorp.com), our investor relations website
(http://investor.amarincorp.com), including but not limited to
investor presentations and investor FAQs, Securities and Exchange
Commission filings, press releases, public conference calls and
webcasts. The information that we post on these channels and
websites could be deemed to be material information. As a
result, we encourage investors, the media, and others interested in
Amarin to review the information that we post on these channels,
including our investor relations website, on a regular basis.
This list of channels may be updated from time to time on our
investor relations website and may include social media
channels. The contents of our website or these channels, or
any other website that may be accessed from our website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
Amarin Contact Information
Investor Relations:Elisabeth Schwartz Amarin Corporation plc
In U.S.: +1 (908) 719-1315 investor.relations@amarincorp.com
Lee M. Stern Trout Group In U.S.: +1 (646) 378-2992
lstern@troutgroup.com Media Inquiries: Ovidio Torres Finn Partners
In U.S.: +1 (312) 329 3911 ovidio.torres@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2023 to Mar 2024